EHI
BPMC

Eagle Health Investments’s Blueprint Medicines BPMC Stock Holding History

Eagle Health Investments’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-170,551
Closed -$8.62M – 29
2022
Q2 		$8.62M Hold
170,551
– – 2.01% 20
2022
Q1 		$10.9M Sell
170,551
-22,088
-11% -$1.59M 2.68% 18
2021
Q4 		$20.6M Buy
192,639
+16,464
+9% +$1.72M 5.03% 7
2021
Q3 		$18.1M Buy
176,175
+35,412
+25% +$3.3M 5.74% 5
2021
Q2 		$12.4M Buy
140,763
+7,600
+6% +$696K 4.25% 12
2021
Q1 		$12.9M Buy
133,163
+71,103
+115% +$7.1M 5.08% 9
2020
Q4 		$6.96M Buy
+62,060
New +$6.54M 4.45% 10

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Eagle Health Investments's BPMC Position: Q3 2022 in Review

Eagle Health Investments sold out of Blueprint Medicines (BPMC) in Q3 2022, closing a stake of 170,551 shares — an estimated $8.62M sold.

Eagle Health Investments first reported a position in BPMC in Q4 2020 and held it in 7 quarters. The position peaked at $20.6M in Q4 2021. 240 funds tracked by Wall St. Rank hold BPMC as of Q3 2022.

  • Eagle Health Investments reported no remaining Blueprint Medicines position as of Q3 2022 after selling out during the quarter.
  • Eagle Health Investments sold 170,551 Blueprint Medicines shares in Q3 2022, an estimated $8.62M.
  • Eagle Health Investments first reported a position in Blueprint Medicines in Q4 2020 and held it in 7 quarters.
  • Eagle Health Investments's Blueprint Medicines position peaked at $20.6M in Q4 2021.
  • 240 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2022.

Based on Eagle Health Investments's 13F filing for Q3 2022, filed 14 Nov 2022.